(Total Views: 548)
Posted On: 09/04/2020 9:10:59 AM
Post# of 148939
The therapy targets a “do-not-eat-me” signal that allows cancer cells to avoid being targeted by the patient’s own immune system, according to I-Mab’s website. The drug blocks the signal, allowing the immune system to engulf and eradicate the malignant cells.
I-Mab’s deal with AbbVie is the latest large transaction in one of the hottest areas of pharmaceutical research: cancer treatments that harness the immune system to fight tumors. Earlier this year, Gilead Sciences Inc. completed the acquisition of immuno-oncology firm Forty Seven Inc. for about $4.9 billion.
https://www.bloomberg.com/news/articles/2020-...na-s-i-mab
SOUNDS LIKE A FAMILIAR MoA
I-Mab’s deal with AbbVie is the latest large transaction in one of the hottest areas of pharmaceutical research: cancer treatments that harness the immune system to fight tumors. Earlier this year, Gilead Sciences Inc. completed the acquisition of immuno-oncology firm Forty Seven Inc. for about $4.9 billion.
https://www.bloomberg.com/news/articles/2020-...na-s-i-mab
SOUNDS LIKE A FAMILIAR MoA
(0)
(0)Scroll down for more posts ▼
